Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. is a development stage life sciences company that creates a platform technology for quantifying and unlocking the complexity of the proteome. The company's main product is the Nautilus Voyager Platform, an end-to-end solution that includes instruments, reagents, consumables, and software analysis. The Voyager instrument is a high-resolution optical imaging system with integrated fluidics and liquid handling subsystems. It deposits protein libraries onto a flow cell and processes labeled multi-affinity reagent binding and imaging cycles to decode and quantify proteins in biological samples. The company also offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to support multi-cycle analysis runs.

Nautilus Biotechnology is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol NAUT. Its stock trades in US dollars (USD). The company is headquartered in Seattle, Washington, United States, and operates primarily in the US market.

Nautilus Biotechnology operates in the Healthcare sector and is classified under the Biotechnology industry. As a development stage life sciences company, it focuses on creating technology to study the proteome—the entire set of proteins expressed by an organism—which has applications in drug discovery, diagnostics, and personalized medicine.

Nautilus Biotechnology is headquartered in Seattle, Washington, United States. The company primarily serves the US market, but it has research collaboration agreements with several notable institutions, including Genentech, the Buck Institute, the Allen Institute, Cornell University, the Qatar Foundation, and the Michael J. Fox Foundation. These collaborations indicate a global reach in research partnerships, though the company's commercial focus remains on the United States.

Nautilus Biotechnology is a development stage company, meaning it has not yet generated significant revenue from product sales. Its business model revolves around developing and commercializing the Nautilus Voyager Platform, which includes instruments, consumables (such as flow cells and affinity reagents), and software. The company plans to generate revenue through the sale of these products and related services. Additionally, it engages in research collaboration agreements with partners like Genentech and the Michael J. Fox Foundation, which may provide funding and validation for its technology. As a development stage company, it focuses on advancing its platform toward commercialization.